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INTRODUCTION
Inherited epidermolysis bullosa (EB)
represents a clinically and genetically
heterogeneous group of genodermatoses
characterized by skin fragility, i.e.,
blisters and erosions of skin and mucous
membranes in response to minor friction
or mechanical trauma (Figure 1a–e). EB
comprises a broad spectrum of pheno-
types, ranging from severe cutaneous
and extracutaneous involvement caused
by severely compromised dermal–epi-
dermal or intra-epidermal adhesion to
discrete traits caused by subtle molecu-
lar defects. On the basis of our current
knowledge, mutations in 17 different
genes account for the genetic and allelic
heterogeneity of EB (Figure 1). The EB-
associated genes code for intracellular,
transmembrane, or extracellular proteins
involved in cytoskeleton, cell–cell or
cell–matrix adhesion (Figure 1f). The
main adhesive structures in the skin,
i.e., desmosomes, hemidesmosomes,
basement membrane, and anchoring
fibrils represent supramolecular protein
complexes and networks that not only
assure the integrity and mechanical
stability of the integument, but also
regulate cellular functions by transmit-
ting signals between the cells and their
extracellular milieu. Therefore, the
heterogeneity and the partial overlap
between clinical and molecular EB
subtypes are not surprising if one con-
siders the high density of molecules and
their complex interactions in cell–cell
and cell–matrix adhesions.
HISTORICAL PERSPECTIVE
The term EB (implying involvement
limited to epidermis) was coined by
Koebner more than 120 years ago
(Koebner, 1886). It has remained in
use until today, although this group of
disorders now encompasses the entire
spectrum of known skin fragility dis-
orders, a concept sometimes difficult to
comprehend by the patients and some
clinicians as well. In the first half of the
20th century, the major achievements
in the EB field consisted of defining
clinical entities and distinguishing bet-
ween inherited and acquired forms of
bullous diseases. In the 1960s, ultra-
structural studies led to the classifica-
tion of EB into three major types—
simplex, junctional, and dystrophic—
based on the precise level of tissue
separation (Pearson, 1962; Hashimoto
et al., 1975; Rodeck et al., 1980; first
milestone). In the 1970s and 1980s, a
plethora of clinically distinct EB sub-
types were defined, often designated by
eponyms. In particular, the monograph
published in 1971 by Tobias Gedde-
Dahl included meticulously collected
data on more than 100 patients with EB
(Gedde-Dahl, 1971).
In the 80s, development of immuno-
fluorescence techniques and genera-
tion of polyclonal and monoclonal
antibodies resulted in the identification
of the first molecules causally involved
in EB and the establishment of first
molecular criteria for diagnosis using
immunofluorescence mapping of the
dermal–epidermal junction ((Hintner
et al., 1981), reviewed in (Fine,
1987)). This was the second milestone
in our pathogenetic understanding of
this group of disorders.
In parallel, rapid improvements
in protein biochemical methods and
recombinant protein expression sys-
tems facilitated the isolation and mole-
cular characterization of the proteins of
the dermal–epidermal basement mem-
brane zone or their functional domains.
Using molecular tools, combined
with immunoelectron microscopy,
such pivotal adhesion proteins as lami-
nin-332 (previously kalinin, laminin 5)
and collagen VII were identified as
structural components of the hemides-
mosomes and the anchoring fibrils
(Sakai et al., 1986; Bruckner-Tuderman
et al., 1987, 1988; Marinkovich et al.,
1992, 1993; Urban, 2012). All the
new knowledge and diagnostic ad-
vances acquired during this decade
were reflected in the revised clinical
and laboratory criteria for EB, pub-
lished in 1991, which split EB into
numerous clinical subtypes (Fine et al.,
1991).
The 1990s were marked by rapid
progress in genetics, which was based
on the development of molecular
genetic methods, including gene clon-
ing, linkage analyses for gene mapping,
and efficient DNA sequencing. In
1991, KRT14 mutations were found to
cause EB simplex, the most common
EB type (Coulombe et al., 1991).
Thereafter, in rapid succession, map-
ping and discovery of the genetic
defects underlying several different EB
subtypes were reported (Ryynanen
et al., 1991a, 1991b, 1992; Hovnanian
et al., 1992; Christiano et al., 1993;
Hilal et al., 1993; McGrath et al., 1995;
Li and Uitto, 2012). Molecular genetic
diagnostics became available, but
were still labor-intensive, expensive,
and dependent on pre-screening. In
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parallel to the elucidation of new
genetic defects and different kinds
of mutations in the known genes,
researchers started to explore the
molecular mechanisms underlying
keratinocyte fragility in EB simplex
and dermal–epidermal destabilization
in junctional and dystrophic EB. In
1997, revertant mosaicism, i.e., genetic
reversion of inherited mutations was
recognized clinically in patients with
junctional EB and demonstrated
on molecular genetic level (Jonkman
et al., 1997). For many years, this
phenomenon of natural healing was
considered rare and described only in
isolated cases. Recently, however, it
has become clear that revertant mosai-
cism occurs in most, if not all EB types,
and is more widespread than expected
(Lai-Cheong et al., 2011; Kiritsi et al.,
2012; McLean and Irvine, 2012).
CLINICAL CLASSIFICATION
In the beginning of the 21st century,
a rich body of molecular genetic data
on EB was already available. Muta-
tion databases (http://www.interfil.org,
https://portal.biobase-international.com/
hgmd/) and patient registries (https://
grenada.lumc.nl/LOVD2, http://www.
deb-central.org/molgenis.do, http://www.
col7.info) facilitated both the study of
genotype–phenotype correlations and
the genetic counselling. Together with
the knowledge acquired on biochem-
ical and cell biological disease mechan-
isms, these data served as prerequisite
for rational disease classifications. Dur-
ing the first decade of the 21st century,
two revisions of the EB classification
were needed to reflect the complexity
and significant developments in the
field (Fine et al., 2000, 2008). Sub-
stantial advances in understanding the
molecular basis of many old and new
EB forms led to the tendency to avoid
splitting of the disease into too many
sub-entities and to reduce the use of
eponyms. However, this is in part
counteracted by continuous progress
relating to discovery of new genes in
rare EB subtypes.
CLINICAL AND GENETIC FEATURES
OF EB SUBTYPES
The most extensive changes have con-
cerned EB simplex. Although the vast
majority of EB simplex cases is caused
by keratin 5/14 mutations (Figure 1b),
several new causative genes have been
identified. BPAG1e (dystonin isoform
4) and plectin mutations can cause
cytolysis of basal keratinocytes and
mild blistering, and may account for
Figure 1. Clinical and molecular heterogeneity of epidermolysis bullosa (EB). (a) Residual superficial erosions after blistering on the heel of a boy with
acral peeling syndrome and transglutaminase 5 mutations, p.[G113C];[L214CfsX15]. (b) Grouped blisters and crusts on the foot of a girl with EB simplex
Dowling-Meara caused by the keratin 14 mutation, p.R125C. (c) The right hand of a woman with junctional EB–other and collagen XVII mutations,
p.[M1T];[R1226X], showing blisters, erosions, crusts, hypopigmentation, and nail loss. (d) Feet of a boy with dystrophic EB with COL7A1 mutations
(c.[425A4G];[3276G4A]) demonstrate crusts, extensive scarring, webbing of the toes, and nail loss. (e) The left hand of a young man with Kindler syndrome
homozygous for the frameshift mutation in the FERMT1 gene p.[D153RfsX3];[D153RfsX3], demonstrates pronounced skin atrophy, incipient webbing
of the finders, and nail dystrophy. (f) The left panel shows immunofluorescence staining of normal human skin with antibodies to desmoplakin (red) and collagen
IV (green); nuclei are in blue. The levels of skin cleavage, which correspond to the main EB types and subtypes, and the defective proteins are indicated
on the right side of the figure.
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at least some of the molecularly un-
solved EB simplex cases (Rezniczek
et al., 2010; Liu et al., 2012). Further-
more, the spectrum of EB simplex has
extended to include subtypes with
cleavage in the suprabasal epidermal
layers, e.g., the plakophilin deficiency
and the lethal acantholytic EB. These
very rare new forms are caused by
genetic defects of desmosomal proteins
(McGrath et al., 1997; Jonkman et al.,
2005; Pigors et al., 2011). Hence, our
vision on EB has extended to include
conditions with perturbed cell–cell
adhesion, in which the clinical picture
is dominated by skin erosions rather
than blisters. The molecular basis of
EB simplex superficialis has remained
unclear (Fine et al., 2008), as a muta-
tion in the collagen VII gene, asso-
ciated with dominant dystrophic EB,
was identified in the original family
(Fine et al., 1989; Martinez-Mir et al.,
2002). In a number of patients
with superficial blisters and erosions
(Figure 1a), transglutaminase 5 muta-
tions indicative of acral peeling skin
syndrome have been disclosed (Kiritsi
et al., 2010; Pigors et al., 2012). We
believe that it is time to classify acral
peeling skin syndrome as a skin fragility
disorder, rather than a form of ichthyo-
sis as it is now (Oji, 2010).
The classification of the junctional EB
was simplified by distinction of the lethal
(Herlitz) subtype from the others, which
were collectively designated as junc-
tional EB–other. Junctional EB Herlitz is
defined by loss of laminin-332, and it
remains one of the most severe forms of
EB. Junctional EB–other encompasses
diverse phenotypes, in which blistering
ranges from lifelong, generalized (Figure
1c), to late onset, mild, and localized,
depending on the residual expression
or activity of the mutated protein. The
laryngo-onycho-cutaneous syndrome
was included as a junctional EB variant,
as it has similar clinical features and is
associated with mutations in the a3-
chain of laminin-332. Very recently,
integrin a3 mutations were discovered
in three patients with a new complex
phenotype, including junctional EB,
congenital nephrotic syndrome, and
interstitial lung disease (Has et al., 2012).
All dystrophic EB subtypes are
caused by mutations in the gene
encoding collagen VII, the main com-
ponent of the anchoring fibrils. The
clinical presentations vary from severe
generalized blistering and scarring
(Figure 1d) to sole nail dystrophy
without skin blistering. Although more
than 600 COL7A1 gene mutations are
known to date, the genotype–pheno-
type correlations are understood only
in part. The heterogeneity of the allelic
subtypes is likely to result from the
variable expression and function of
mutated collagen VII, with the complex
interplay of genetic and environmental
modifiers.
Because of the variable (mixed)
level of skin cleavage, the Kindler
syndrome was recognized as a distinct
type of EB. It is clinically characterized
by skin blistering during childhood and
progressive poikiloderma, skin and
mucosal scarring, and predisposition
to epithelial skin cancer in adulthood
(Figure 1e). Mutations in the FERMT1
gene encoding kindlin-1 underlie this
rare autosomal recessive genodermato-
sis. From a molecular point of view,
the Kindler syndrome and the EB with
integrin a3 mutations may be classified
separately as focal adhesion disorders,
because they impair the functions of
focal adhesions, adherence, and signal-
ling platforms, which are needed for
epidermal cell adhesion and migration.
CLINICAL PERSPECTIVE
By the end of 2011, more than 1250
different mutations in 17 genes respon-
sible for EB were included in the
Human Gene Mutation Database
Professional release (2011.4; Harel and
Christiano, 2012). In several countries,
mutation analysis is now routinely
available, every patient having the right
to know his/her own mutation. This
development expanded the spectrum of
disorders encompassed by the term EB
and represents the basis for individua-
lized molecular therapeutic approaches
(Cho et al., 2012; Uitto, 2012).
Many preliminary studies regarding
translational approaches in EB have
been published during the last decade
(Mavilio et al., 2006; Fritsch et al.,
2008; Wong et al., 2008; Remington
et al., 2009; Wagner et al., 2010; Cho
et al., 2012). In the future, the imple-
mentation of novel biologically valid
therapies must take into account the
balance between the gain and risk. No
unique solution will be available for all
patients, but the success will rather
come with personalized therapies
adapted to the individual molecular
and clinical constellation (Uitto, 2012).
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